Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Czechia / NCT07112937
Recruiting Observational

The Effect of Multimodal Treatment of Rectal Cancer on Circulating Tumor Cells: A Prospective, Observational Study

NCT07112937 · tracked via the Priya Life Science Czechia tracker
Sponsor
The Institute of Molecular and Translational Medicine, Czech Republic
Phase
Observational
Started
2023-05-02
Last updated
2025-08-08

Condition(s) studied

Rectal Cancer Patients

Study summary

The prospective study will focus on patients undergoing multimodal treatment for rectal cancer. The main objective of the study will be to monitor changes in circulating tumor cells (CTCs) in the peripheral blood of patients during multimodal treatment. For each patient enrolled in the study, peripheral blood samples will be collected at specified time intervals to determine the presence and quantity of CTCs.

The CTCs levels will be compared among rectal cancer patients with neoadjuvant chemoradiotherapy and without neoadjuvant chemotherapy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: rectal cancer - Exclusion Criteria: no other cancer \-

Primary outcome measure(s)

  • Levels of circulating tumor cells in peripheral blood — The levels of circulating tumor cells will be measured in 5 time points: before neoadjuvant chemoradiotherapy, in 3. week of chemoradioterapy, before surgery, one week after surgery and one month after surgery.
    The levels of circulating tumor cells will be measured in rectal cancer patients

Trial sites (1)

FacilityCityRegionStatus
University Hospital Ostrava Ostrava Czechia Recruiting

More The Institute of Molecular and Translational Medicine, Czech Republic trials in Czechia

Exhaled Breath Condensate Analysis in Mechanically Ventilated Patients Recruiting
Study of Early Cancer Biomarkers in Breath Condensate in Population of Individuals With High-Risk of Lung Cancer Undergoing LDCT Screening. Recruiting
Biomarkers of Endometrial Receptivity Recruiting
Self-sampling for Non-attenders to Cervical Cancer Screening Recruiting
Assesment of Multiomics Profiles in Health and Disease. Recruiting

Other trials for the same condition

Rectal Cancer CTC Trial Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07112937 on ClinicalTrials.gov ↗ ← All trials in Czechia